Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study.

cancer colorectal cancer fluorescence imaging indocyanine green lymph node nodal staging prognosis sentinel lymph node detection treatment

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
14 Aug 2020
Historique:
received: 26 01 2020
accepted: 15 06 2020
revised: 04 06 2020
pubmed: 20 6 2020
medline: 20 6 2020
entrez: 20 6 2020
Statut: epublish

Résumé

Nodal staging is a major concern in colorectal cancer as it is an important prognostic factor. Several techniques that could potentially improve patient treatment and prognosis have been developed to increase the accuracy of nodal staging. Sentinel lymph node detection has been shown to accurately reflect nodal status in various tumors and has become the standard procedure in nodal staging of breast cancer and melanoma. However, in colorectal cancer, sentinel lymph node detection techniques are still controversial as the sensitivity reported in the literature varies from one study to another. Recently, indocyanine green fluorescence-guided surgery has been reported to be a useful technique for detection of macroscopic and microscopic metastatic deposits in lymph nodes after intravenous administration of indocyanine green dye. However, no studies have focused on the potential role of sentinel lymph node detection after systemic administration of indocyanine green dye, so-called systemic sentinel lymph nodes, or on the correspondence between the identification of the sentinel lymph node by standard local injection techniques and the detection of fluorescent lymph nodes with this new approach. The aim of this protocol is to validate the concept of sentinel lymph nodes identified by fluorescence imaging after intravenous injection of indocyanine green dye and to compare the sentinel lymph nodes identified by fluorescence imaging with sentinel lymph nodes detected by the standard blue dye technique. This study (SeLyNoFI; Sentinel Lymph Nodes Fluorescence Imaging) is a diagnostic, single-arm, open-label feasibility study, including patients with colorectal adenocarcinoma with or without metastatic disease who are admitted for elective colorectal resection of the primary tumor. This study evaluates the feasibility of a new approach for improving the accuracy of nodal staging using fluorescence imaging after intravenous administration of indocyanine green dye. Sensitivity, positive predictive value, and accuracy of the classical blue dye technique and of the investigatory fluorescence imaging technique will be calculated. Translational research will be proposed, if applicable. As of June 2020, this study has been registered. Submission for ethical review is planned for September 2020. The potential correlation between the two different approaches to detect sentinel lymph nodes offers new strategies for improving the accuracy of nodal staging in colorectal cancer. This new concept of the systemic sentinel lymph node and a greater understanding of the interactions between systemic sentinel lymph nodes and standard sentinel lymph nodes may provide important information regarding the underlying mechanism of primary tumor lymphatic drainage. The enhanced permeability and retention effect can also play a role in the fluorescence of systemic sentinel lymph nodes, especially if these lymph nodes are inflamed. In this case, we can even imagine that this new technique will highlight more instances of lymph node-positive colorectal cancer. PRR1-10.2196/17976.

Sections du résumé

BACKGROUND BACKGROUND
Nodal staging is a major concern in colorectal cancer as it is an important prognostic factor. Several techniques that could potentially improve patient treatment and prognosis have been developed to increase the accuracy of nodal staging. Sentinel lymph node detection has been shown to accurately reflect nodal status in various tumors and has become the standard procedure in nodal staging of breast cancer and melanoma. However, in colorectal cancer, sentinel lymph node detection techniques are still controversial as the sensitivity reported in the literature varies from one study to another. Recently, indocyanine green fluorescence-guided surgery has been reported to be a useful technique for detection of macroscopic and microscopic metastatic deposits in lymph nodes after intravenous administration of indocyanine green dye. However, no studies have focused on the potential role of sentinel lymph node detection after systemic administration of indocyanine green dye, so-called systemic sentinel lymph nodes, or on the correspondence between the identification of the sentinel lymph node by standard local injection techniques and the detection of fluorescent lymph nodes with this new approach.
OBJECTIVE OBJECTIVE
The aim of this protocol is to validate the concept of sentinel lymph nodes identified by fluorescence imaging after intravenous injection of indocyanine green dye and to compare the sentinel lymph nodes identified by fluorescence imaging with sentinel lymph nodes detected by the standard blue dye technique.
METHODS METHODS
This study (SeLyNoFI; Sentinel Lymph Nodes Fluorescence Imaging) is a diagnostic, single-arm, open-label feasibility study, including patients with colorectal adenocarcinoma with or without metastatic disease who are admitted for elective colorectal resection of the primary tumor. This study evaluates the feasibility of a new approach for improving the accuracy of nodal staging using fluorescence imaging after intravenous administration of indocyanine green dye. Sensitivity, positive predictive value, and accuracy of the classical blue dye technique and of the investigatory fluorescence imaging technique will be calculated. Translational research will be proposed, if applicable.
RESULTS RESULTS
As of June 2020, this study has been registered. Submission for ethical review is planned for September 2020.
CONCLUSIONS CONCLUSIONS
The potential correlation between the two different approaches to detect sentinel lymph nodes offers new strategies for improving the accuracy of nodal staging in colorectal cancer. This new concept of the systemic sentinel lymph node and a greater understanding of the interactions between systemic sentinel lymph nodes and standard sentinel lymph nodes may provide important information regarding the underlying mechanism of primary tumor lymphatic drainage. The enhanced permeability and retention effect can also play a role in the fluorescence of systemic sentinel lymph nodes, especially if these lymph nodes are inflamed. In this case, we can even imagine that this new technique will highlight more instances of lymph node-positive colorectal cancer.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
PRR1-10.2196/17976.

Identifiants

pubmed: 32554370
pii: v9i8e17976
doi: 10.2196/17976
pmc: PMC7455862
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e17976

Informations de copyright

©Gabriel Liberale, Sophie Vankerckhove, Fikri Bouazza, Maria Gomez Galdon, Denis Larsimont, Michel Moreau, Pierre Bourgeois, Vincent Donckier. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 14.08.2020.

Références

J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Int J Colorectal Dis. 2012 Mar;27(3):319-24
pubmed: 21912878
Gastroenterol Clin Biol. 2007 Mar;31(3):281-5
pubmed: 17396086
Eur J Surg Oncol. 2015 Sep;41(9):1256-60
pubmed: 26081552
J Clin Oncol. 2014 May 1;32(13):1365-83
pubmed: 24663048
Ann Surg Oncol. 2013 Jul;20(7):2357-63
pubmed: 23440551
Cancer. 1997 Jul 15;80(2):188-92
pubmed: 9217028
Ann Surg Oncol. 2010 Jan;17(1):144-51
pubmed: 19774415
Ann Oncol. 2010 May;21 Suppl 5:v194-7
pubmed: 20555080
Breast Cancer Res Treat. 2010 Jun;121(2):373-8
pubmed: 20140704
Ann Surg Oncol. 2001 Oct;8(9 Suppl):94S-98S
pubmed: 11599912
Hepatogastroenterology. 2007 Jan-Feb;54(73):81-4
pubmed: 17419236
Dig Surg. 2008;25(2):103-8
pubmed: 18379188
Dtsch Arztebl Int. 2010 Aug;107(31-32):552-6
pubmed: 20827353
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
J Clin Oncol. 2015 Dec 10;33(35):4176-87
pubmed: 26527776
Lancet Oncol. 2011 Jun;12(6):540-50
pubmed: 21549638
J Surg Oncol. 2016 Sep;114(3):348-53
pubmed: 27264200
Gynecol Oncol. 2012 Jan;124(1):78-82
pubmed: 21996262
Anticancer Res. 2006 May-Jun;26(3B):2307-11
pubmed: 16821607
Anticancer Res. 2016 Sep;36(9):4853-8
pubmed: 27630340

Auteurs

Gabriel Liberale (G)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Sophie Vankerckhove (S)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Fikri Bouazza (F)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Maria Gomez Galdon (M)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Denis Larsimont (D)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Michel Moreau (M)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Pierre Bourgeois (P)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Vincent Donckier (V)

Institut Jules Bordet, Belgian Comprehensive Cancer Center, Université Libre de Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.

Classifications MeSH